Sugi Predict

Sugi Predict / Compounds / SCHEMBL2470176

SCHEMBL2470176

SCHEMBL2470176

Cc1cc2ccnc(Cl)c2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 1/20 0.41
▸ DYRK1A Q13627 1/20 0.40
▸ GAA P10253 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CYP19A1 P11511 2/20 0.36
▸ MAPK8 P45983 1/20 0.35
▸ KDM4E B2RXH2 4/20 0.35
▸ DAO P14920 1/20 0.34
▸ JAK2 O60674 2/20 0.33
▸ ATAD2 Q6PL18 3/20 0.33
▸ CYP2A6 P11509 1/20 0.32
▸ KEAP1 Q14145 1/20 0.32
▸ BRD4 O60885 2/20 0.32
▸ MAPT P10636 1/20 0.32
▸ PIK3CG P48736 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23478381 0.80 RXFP1 (0.38) RXFP1DYRK1ADAOJAK2BRD4
SCHEMBL8266924 0.77 NOS2 (0.41) GAAHTTSMN1; SMN2TDP1L3MBTL1
SCHEMBL23478930 0.77 RXFP1 (0.38) RXFP1DYRK1ADAO
SCHEMBL1735901 0.76 IDO1 (0.48) JAK2MAPT
SCHEMBL7217640 0.74 AXL (0.40) DYRK1ASMN1; SMN2CYP19A1MAPK8KDM4E
SCHEMBL4275395 0.74 CYP2A6 (0.42) RXFP1DYRK1ADAOCYP2A6MAPT
SCHEMBL25581554 0.74 RXFP1 (0.40) RXFP1DYRK1AMAPT
SCHEMBL4266746 0.73 KDM4C (0.45) RXFP1DYRK1ATDP1CYP19A1DAO
SCHEMBL13656919 0.73 RXFP1 (0.36) RXFP1DYRK1ASMN1; SMN2DAOATAD2
Hydrochloric Acid SCHEMBL4276336 0.72 RXFP1 (0.35) RXFP1DYRK1ASMN1; SMN2DAOATAD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021113690-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 — — WO disclosed
WO-2021113682-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 — — WO disclosed
EP-2955185-B1 POLYCYCLIC SUBSTITUTED PYRAZOLE KINASE ACTIVITY INHIBITORS AND USE THEREOF SHANGHAI FOSUN PHARMACEUTICAL DEV CO LTD (CN) 2021-01-06 — — EP disclosed
EP-1787991-B2 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICALS CO (JP) 2020-06-24 — — EP disclosed
US-20180148446-A1 PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICALS CO (JP) 2018-05-31 — — US disclosed
US-9550792-B2 Polycyclic substituted pyrazole kinase activity inhibitors and use thereof SHANGHAI FOSUN PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) 2017-01-24 — — US disclosed
US-9364466-B2 Heterocyclic compounds as protein kinase inhibitors DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-06-14 — — US disclosed
EP-2714688-B1 HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS DAIICHI SANKYO CO LTD (JP) 2016-02-24 — — EP disclosed
US-20150368259-A1 Polycyclic Substituted Pyrazole Kinase Activity Inhibitors and Use Thereof SHANGHAI FOSUN PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) 2015-12-24 — — US disclosed
EP-2955185-A1 POLYCYCLIC SUBSTITUTED PYRAZOLE KINASE ACTIVITY INHIBITORS AND USE THEREOF China Pharmaceutical University (CN) 2015-12-16 — — EP disclosed
US-20150157613-A1 HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-06-11 — — US disclosed
US-8980911-B2 Heterocyclic compounds as protein kinase inhibitors DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-03-17 — — US disclosed
US-20140155398-A1 HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-06-05 — — US disclosed
CN-103012428-A 4-(five-membered heterocycle pyrimidin/substituted pyridine) amino-1H-3-pyrazolecarboxamide CDK (cyclin dependent kinase)/Aurora dual inhibitor and application thereof UNIV CHINA PHARMA 2013-04-03 — — CN disclosed
WO-2012160464-A1 HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-11-29 — — WO disclosed
EP-1787991-B1 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICAL (JP) 2011-10-05 — — EP disclosed
US-20070293532-A1 Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use TAKEDA PHARMACEUTICAL COMPAN6Y LIMITED (JP) 2007-12-20 — — US disclosed
EP-1787991-A1 PYRROLOÝ2,3-c¨PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2007-05-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148446-A1 PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE PGA5, ATP6AP1, PPA1 RXFP1 4402/4885DYRK1A 2882/4885GAA 212/4885
US-20150157613-A1 HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS MAP3K1, JAK2, AKT1 RXFP1 1314/4885DYRK1A 680/4885GAA 2254/4885
US-20150368259-A1 Polycyclic Substituted Pyrazole Kinase Activity Inhibitors and Use Thereof MAP3K5, MAP3K19, MAP3K3 RXFP1 4731/4885DYRK1A 546/4885GAA 2122/4885
US-20070293532-A1 Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use PGA5, ATP6AP1, PPA1 RXFP1 4402/4885DYRK1A 2882/4885GAA 212/4885
US-20140155398-A1 HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS MAP3K1, JAK2, AKT1 RXFP1 1314/4885DYRK1A 680/4885GAA 2254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.